Company News

The Sydney company has become the first in Australia to earn a manufacturing licence for viral vectors, a milestone it says strengthens the nation's capacity to make advanced gene and cell therapies at home rather than relying on overseas suppliers.

The grant, announced by Neurizon, will finance an Expanded Access Protocol for NUZ-001, the company's lead drug candidate for amyotrophic lateral sclerosis, commonly known as ALS or motor neurone disease.

Radiopharm Theranostics has reported encouraging early results from a Phase 1 imaging trial of its experimental agent RAD301 in patients with pancreatic ductal adenocarcinoma, one of the most lethal and hardest-to-treat forms of cancer.

CLINUVEL, a Melbourne- and Singapore-based biopharmaceutical company, has completed development of a proprietary single-use device designed to administer controlled-release drug formulations under the skin.

A hospital in Madrid has reached a notable milestone for OncoSil Medical, with the Australian medical device company confirming that its device has now treated its 100th patient in Spain.

Emyria is on the verge of opening its first clinic in Sydney, marking the company's entry into New South Wales and extending its national network of intensive mental health services into Australia's most populous state.

OncoSil Medical has secured $5.6 million in fresh capital from its three biggest institutional shareholders, giving the Sydney-based medical device company the financial firepower to launch its targeted radiation therapy in the United States and Australia after years of regulatory work.

Arovella Therapeutics has taken a step toward treating blood cancer patients with donor-derived cells rather than their own, announcing that it has released its first clinical manufacturing batch of ALA-101 and opened its first trial site at The Alfred Hospital in Melbourne.

Neurizon Therapeutics, the Melbourne-based biotechnology company developing a treatment for the fatal neurological disease ALS, has appointed Dr Chris Bremer as its new chief executive officer.

Melbourne-based Immuron is preparing to bring its digestive health product PROIBS to American shelves after striking an exclusive distribution deal with Swedish life science company Calmino Group AB.

Prescient Therapeutics has reached an important enrolment milestone in its Phase 2a trial of PTX-100 for patients with relapsed or refractory cutaneous T-cell lymphoma, setting the company up for a planned dose optimisation review in December.

ENA Respiratory has welcomed $2.98 million in funding from Biointelect Venturer to support its first Australian study of INNA-051 in adults with asthma, expanding the clinical program for a once-weekly nasal spray intended to strengthen the body’s early defences against common respiratory viruses.